AtheroGenics Reports ARISE Trial Results for AGI-1067 ( alprograms in rheumatoid arthritis and...)

AtheroGenics Reports ARISE Trial Results for AGI-1067

al programs in rheumatoid arthritis and asthma utilizing its proprietary vascular protectant® technology. For more information about AtheroGenics, please visit http://www.atherogenics.com.

Disclosure Regarding Forward-Looking Statements

This press release contains forward-looking statements that involve significant risks and uncertainties, including preliminary summary statements relating to the analysis of AtheroGenics' ARISE study for AGI-1067 and preliminary summary statements relating to the potential efficacy and safety profile of AGI-1067. These and other statements contained in this press release that relate to events or developments that we expect or anticipate will occur in the future are deemed to be forward-looking statements, and can be identified by words such as "believes," "intends," "expects" and similar expressions. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performances to differ materially from those referred to in such statements. AtheroGenics cautions investors not to place undue reliance on the forward-looking statements contained in this release. The preliminary results discussed in this release may not be confirmed upon full analysis of the detailed results of the ARISE study and additional information relating to the safety, efficacy or tolerability of AGI-1067, may be discovered upon further analysis of trial data. In addition, our forward-looking statements are subject to a number of factors that could cause actual outcomes to differ materially from those expressed or implied in our forward-looking statements, including that the Food and Drug Administration might not allow us to conduct further studies of the efficacy of AGI-1067 for the same or new endpoints, and, to the extent approved, additional clinical trial wo
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia

Post Your Comments:

(Date:12/15/2009)... Calif., Dec. 15 Dakim, Inc. and Alzheimer,s ... for Loved Ones, Brain Health Contest, designed to help ... of dementia and Alzheimer,s disease. All five winners will ... designed specifically to help seniors preserve their brain health ... in senior living communities across the country. ...

(Date:12/15/2009)... NASHVILLE, Tenn., Dec. 15 Cumberland ... announced new top-line results for a ... for Oral Solution, a prescription laxative packaged as ... liquid forms. ,, Kristalose is the only prescription-strength ... 14-day period, 50 patients with a recent diagnosis ...

(Date:12/15/2009)... Dynatronics Corporation (Nasdaq: DYNT ) ... to provide therapy equipment and rehab supplies to ... of physical, occupational and speech therapy clinics. ,, ... Providers," said Larry K. Beardall, executive vice president ... network of 1,100 clinics is the largest rehabilitation ...

Breaking Medicine Technology:5 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 2 5 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 3 Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study 2 Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study 3 Dynatronics Inks Preferred Vendor Agreement with 1,100 Member Preferred Therapy Providers, Inc. 2 Approved lymphoma drug shows promise in early tests against bone cancer 60780 1 Approved lymphoma drug shows promise in early tests against bone cancer 60780 2 Mom was right 3A Nice guys dont always finish last 60778 1 Mom was right 3A Nice guys dont always finish last 60778 2 Fetus Learns Intonations of Mothers Tongue 60775 1 Fetus Learns Intonations of Mothers Tongue 60775 2 Fetus Learns Intonations of Mothers Tongue 60775 3

[0] 5 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's [0] Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study [0] Dynatronics Inks Preferred Vendor Agreement with 1,100 Member Preferred Therapy Providers, Inc.

... First-in-class treatment for inhalation anthrax -ROCKVILLE, Md., May ... HGSI ) today announced that it has ... U.S. Food and Drug Administration (FDA) for its ... treatment of inhalation anthrax. (Logo: ...

... /PRNewswire/ -- Ridge Diagnostics, Inc., a neurodiagnostic ... first-in-class, proprietary blood test for Major Depressive Disorder(MDD), will ... Biomarker Blood Test to Aid in Diagnosis, Treatment and ... Psychiatric Association Annual Meeting, May 20, 2009. The blood ...

Other Medicine Technology:Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM) 2 Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM) 3 Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM) 4 Ridge Diagnostics, Inc. Clinical Data on Blood Test for Depression Presented at American Psychiatric Association Annual Meeting 2

Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)Ridge Diagnostics, Inc. Clinical Data on Blood Test for Depression Presented at American Psychiatric Association Annual Meeting

(Date:12/15/2009)... still too early to say that phthalates ... Dec. 15 (HealthDay News) -- Common chemicals found ... the abnormal growth of breasts in boys, preliminary ... a prominent medical journal for pediatricians, adds fuel ... whose safety has been questioned by some scientists. ...

(Date:12/15/2009)... Study examines potential for injury when doctors decide benefits ... (HealthDay News) -- MRI scans can pose a serious ... U.S. Food and Drug Administration researchers exposed pacemakers to ... electrical voltage produced at the tip of the pacemaker ... patient,s heart. , The exposure to MRI magnetic pulses ...

(Date:12/15/2009)... Accelify is proud to announce the addition ... David will serve as Director of Development in the ... Board of Advisors. ,, David Tokofsky was ... of Education in June 1995. As the Board Member ... 600,000 stretching from Northeast Los Angeles through East Los ...

(Date:12/15/2009)... Mergers and acquisitions are commonplace today. As competitors ... complete a product portfolio they also must face ... ,, A new free, white paper from Howard ... Conservation Program: US Airways ," details how the ... the newly formed company to enhance its occupational ...

(Date:12/15/2009)... NEW YORK, Dec. 15 ... research report is available in its ... of Autoimmune Diseases Therapeutics - Market ... Pipeline and Deals Analysis ... Summary ,, The author has ...

[0] Breast Growth in Boys Might Be Linked to Plastics Chemical [0] Patients With Pacemakers Should Avoid MRI Scans [0] Accelify Announces the Addition of David Tokofsky to its National Board of Advisors [0] New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways [0] Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

... -- China Sky One,Medical, Inc. ("China Sky One ... a,leading fully integrated pharmaceutical company producing external use,over- ... ("PRC"),announced today that it signed an agreement with ... the Company,s prescription,drugs., China Sky One, which ...

... in trials, lengthens survival, study finds , , TUESDAY, July ... that fights malignant brain tumors called glioblastoma multiforme (GBM) ... the outcome, a new report says. , An ... Research says this would mark the first time ...

... Examines Controversial and Relevant Issues ... ... Retirement Living TV (RLTV), the,first network dedicated to people 55+, ... programming -- senior centric,investigative journalism. Viewpoint with Lea Thompson is ...

... a low-sodium diet does not appear to have any ... to new research. , "Despite the clear benefit of ... no therapeutic benefit in the use of a low-sodium ... E. K. Pogson, M.R.C.P., clinical research fellow at the ...

... Most relationships have some degree of,conflict or distance. The ... romantic relationships that end in heartbreak are countless., ... Ferguson states that when a,relationship isn,t working, there will ... that is creating the problem., Bill Ferguson says, ...

... CEO's, are all eagerly awaiting the opening of a new San ... ... 2008 -- Dr. Eben Davis, one of the most successful chiropractors ... bring his vision into reality. Peacock Construction has been in the ...

Other Medicine News:Health News:China Sky One Medical, Inc. Signs Distribution Agreement with Harbin Baolong Pharmaceutical Company 2 Health News:China Sky One Medical, Inc. Signs Distribution Agreement with Harbin Baolong Pharmaceutical Company 3 Health News:Brain Cancer Vaccine's Immune Response Key to Outcomes 2 Health News:Retirement Living TV Announces Series Premiere of Viewpoint with Lea Thompson on July 18, 2008 2 Health News:Low-sodium advice for asthmatics should be taken with a grain of salt 2 Health News:Bill Ferguson's New Book, Get Your Power Back: It Only Takes One Person to Heal a Difficult Relationship 2 Health News:Construction Begins on Executive Express Chiropractic at the SF Embarcadero Center 2

China Sky One Medical, Inc. Signs Distribution Agreement with Harbin Baolong Pharmaceutical Company Brain Cancer Vaccine's Immune Response Key to Outcomes Retirement Living TV Announces Series Premiere of Viewpoint with Lea Thompson on July 18, 2008 Low-sodium advice for asthmatics should be taken with a grain of salt Bill Ferguson's New Book, Get Your Power Back: It Only Takes One Person to Heal a Difficult Relationship Construction Begins on Executive Express Chiropractic at the SF Embarcadero Center

Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....

... Certified by an independent ... 100 specifications of Federal ... guarantees worker confort, reduces ... Clean vinyl meets Class ...

... Seat height: Bench high, 26-31". ... productivity. "Soft Touch" pnuematic control for ... with Static-control casters allow easy mobility. ... ; Decay (from 5000 Volts to ...

Medicine Products:

4V58-R 4V57-R Class 100 Chair Laboratory Chair

( alprograms in rheumatoid arthritis and...)AtheroGenics Reports ARISE Trial Results for AGI-1067,Health